Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Non Small Cell Lung Cancer Clinical Trials

53 recruiting trials for Non Small Cell Lung Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
53
Total Trials
53
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 2NCT03808337

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for...

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 14512 locations
RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGPhase 1 / Phase 2NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab...

Sponsor: Simcha IL-18, Inc.Enrolling: 3166 locations
RECRUITINGNCT05689619

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer...

Sponsor: A.O.U. Città della Salute e della ScienzaEnrolling: 706 locations
RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGNCT06496360

Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer

Mediastinal lymph node metastasis is a common metastasis pathway of non-small cell lung cancer (NSCLC), and its occurrence is closely related to the lymphatic drainage pattern,...

Sponsor: Qilu Hospital of Shandong UniversityEnrolling: 1501 location
RECRUITINGPhase 2NCT06249854

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced...

This is a multicenter, open-label, randomized controlled clinical trial designed to evaluate the efficacy and safety of combination therapy with Bojungikki-tang(BJIKT) and...

Sponsor: Korea Institute of Oriental MedicineEnrolling: 707 locations
RECRUITINGPhase 3NCT07222566

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants...

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with...

Sponsor: PfizerEnrolling: 141017 locations
RECRUITINGPhase 2NCT06127303

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Immunotherapy with programmed death-1(PD-1) inhibitors is now standard therapy for first-line use in patients with driver-negative advanced NSCLC, whether as single-agent or in...

Sponsor: Shanghai Chest HospitalEnrolling: 543 locations
RECRUITINGPhase 2NCT05800587

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in...

Sponsor: Fox Chase Cancer CenterEnrolling: 2801 location
RECRUITINGPhase 1 / Phase 2NCT06303505

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma...

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the...

Sponsor: Tubulis GmbHEnrolling: 25015 locations
RECRUITINGPhase 3NCT06350097

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced...

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas...

Sponsor: AstraZenecaEnrolling: 58220 locations
RECRUITINGPhase 2NCT06300424

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in...

Sponsor: Guangdong Provincial People's HospitalEnrolling: 321 location
RECRUITINGPhase 2NCT05379803

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated...

Sponsor: Hunan Province Tumor HospitalEnrolling: 401 location
RECRUITINGPhase 1NCT05979818

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced...

This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to...

Sponsor: Second Xiangya Hospital of Central South UniversityEnrolling: 61 location
RECRUITINGPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for...

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV...

Sponsor: Bristol-Myers SquibbEnrolling: 100020 locations
RECRUITINGNCT05363319

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small...

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal...

Sponsor: Regeneron PharmaceuticalsEnrolling: 50020 locations
RECRUITINGPhase 1NCT05753722

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid...

Sponsor: Incendia TherapeuticsEnrolling: 27011 locations
RECRUITINGNCT05736029

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using...

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for...

Sponsor: OncoHost Ltd.Enrolling: 3501 location
RECRUITINGPhase 1 / Phase 2NCT06903377

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination...

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,LtdEnrolling: 501 location
RECRUITINGPhase 1NCT03193567

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Sponsor: Ruijin HospitalEnrolling: 151 location
RECRUITINGPhase 1NCT06473961

A Phase Ib Study of GC101 in NSCLC

20 participants are expected to be enrolled for the Phase Ib clinical trial,this trail is expected to be finished in 36 months.

Sponsor: Shanghai Juncell TherapeuticsEnrolling: 201 location
RECRUITINGPhase 2NCT05469022

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung...

Sponsor: Konkuk University Medical CenterEnrolling: 401 location
RECRUITINGNCT06699979

Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes

The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated...

Sponsor: Central South UniversityEnrolling: 3001 location
RECRUITINGPhase 1 / Phase 2NCT06022757

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed...

In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab)...

Sponsor: Evopoint Biosciences Inc.Enrolling: 2041 location
RECRUITINGPhase 1NCT06451497

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With...

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have...

Sponsor: Zumutor Biologics Inc.Enrolling: 1003 locations
RECRUITINGPhase 1NCT05104515

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find...

Sponsor: Oxford Vacmedix UK Ltd.Enrolling: 364 locations
RECRUITINGPhase 1 / Phase 2NCT07070518

Study of GV20-0251 in Participants With Solid Tumor Malignancies

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other...

Sponsor: GV20 TherapeuticsEnrolling: 3503 locations
RECRUITINGPhase 1 / Phase 2NCT04789486

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 1002 locations
RECRUITINGPhase 1NCT06789172

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to...

Sponsor: EpkinEnrolling: 16610 locations
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGPhase 1NCT05227326

AOH1996 for the Treatment of Refractory Solid Tumors

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the...

Sponsor: City of Hope Medical CenterEnrolling: 922 locations
RECRUITINGPhase 1NCT06868849

A Study of JMT203 in Patients With Cancer Cachexia

This is an open-label, multicenter Phase I clinical study aimed at evaluating the safety/tolerability, pharmacokinetics, and effectiveness of JMT203 in patients with cancer...

Sponsor: Shanghai JMT-Bio Inc.Enrolling: 1301 location
RECRUITINGPhase 1NCT07160335

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in...

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17...

Sponsor: Shanghai Henlius BiotechEnrolling: 17420 locations
RECRUITINGPhase 1 / Phase 2NCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with...

Sponsor: University of ArizonaEnrolling: 301 location
RECRUITINGPhase 1NCT05366478

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to...

Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.Enrolling: 151 location
RECRUITINGPhase 2NCT06630611

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After...

Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the...

Sponsor: Vall d'Hebron Institute of OncologyEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part...

Sponsor: Tango Therapeutics, Inc.Enrolling: 19113 locations
RECRUITINGNCT06476093

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Sponsor: The First People's Hospital of LianyungangEnrolling: 461 location
RECRUITINGPhase 2NCT06702826

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases...

Sponsor: Rongrong ZhouEnrolling: 201 location
RECRUITINGPhase 1NCT05430009

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with...

Sponsor: VA Ann Arbor Healthcare SystemEnrolling: 121 location
RECRUITINGPhase 1 / Phase 2NCT03093688

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells....

Sponsor: Shanghai Public Health Clinical CenterEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 1156 locations
RECRUITINGPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and...

Sponsor: SystImmune Inc.Enrolling: 47020 locations
RECRUITINGPhase 3NCT06840704

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Sponsor: Hunan Cancer HospitalEnrolling: 1216 locations
RECRUITINGPhase 1NCT05627960

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal...

Sponsor: A&G Pharmaceutical Inc.Enrolling: 771 location
RECRUITINGPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid...

Sponsor: GenmabEnrolling: 76420 locations
RECRUITINGPhase 1 / Phase 2NCT06362369

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens....

Sponsor: 7 Hills Pharma, LLCEnrolling: 1264 locations
RECRUITINGPhase 1NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...

Sponsor: Ascentage Pharma Group Inc.Enrolling: 1659 locations
RECRUITINGPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid...

Sponsor: Bristol-Myers SquibbEnrolling: 33620 locations

Showing 50 of 53 trials.Search all Non Small Cell Lung Cancer trials